Welcome

Welcome to the Carolina BioOncology Institute (CBI).  We are a cancer therapy and research institute.  Our staff are dedicated to advancing the field of cancer research by making available the latest developments in therapeutic options.  CBI has developed an early phase clinical trial program which represents the cutting edge in immunotherapy and personalized cancer options.  Additionally, CBI is the incubator for BioCytics, a research and development firm working to identify novel drug targets.  We are excited that you are considering a visit to our clinic and we look forward to providing you with the  most recent clinical trial options and the highest quality care.

 

 

Recent Clincial Trials

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Roche-Genentech
Status: Beginning of recruitment is pending for this study
More Details

A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study to Investigate the Effect of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of 960 mg of Vemurafenib

Sponsor: Roche
Status: This study is currently recruiting participants.
More Details

A Phase 2, Open-Label, Multicenter STudy of PSMA ADC in Subjects with Castration-Resistant Metastatic Prostate Cancer (CRMPC)

Sponsor: PSMA Development Company
Status: This study is currently recruiting participants.
More Details

Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb
Status: This study is currently recruiting participants.
More Details

A Study to Determine Whether Necitumumab (IMC-11F8) Monotherapy Affects the Corrected QT (QTc) Interval in Subjects with Advanced Solid Tumors

Sponsor: ImClone
Status: This study is currently recruiting participants.
More Details

Protocol GP28328: A Phase IB Study of the Safety and Pharmacology of MPDL3280A Administered with Bevacizumab or With Bevacizumab Plus FOLFOX in Patients with Advanced Solid Tumors

Sponsor: Genentech
Status: This study is currently recruiting participants.
More Details

Protocol PCD4989g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors of Hematologic Malignancies

Sponsor: Genentech
Status: This study is currently recruiting participants.
More Details

Latest News

Relay for Life

May 8th, 2013

At Carolina BioOncology, we have a passion for clinical trials.  Our goal is to make new developments in cancer treatment available to our patients.  These developments take research, and research takes dedicated scientist, administrators…..and advocates!  There is no better advocate than those with cancer, cancer survivors, and family, friends, and co-workers of those with cancer. [...]

READ MORE

We’re brand new for Spring!

March 18th, 2013

What’s new?  Our website that’s what!  Please take a moment to peruse the new site.  We hope that it is both informative and enjoyable.  We have tried to make our site easier to navigate, more streamlined, and packed with information that is important to you.  Whether you’ve been one of our patient for years or [...]

READ MORE

pad-pdf

9801 Kincey Ave,
Suite 145 Bostick Building
Huntersville, NC 28078

Get Directions

Social Updates